HepaVec AG
Berlin, Berlin, Germany
About HepaVec AG
HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $5.9M
- Funding stage: M&A
- Last round: Series A (May 2000)
- Phone: +49 30 94892282
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/hepavec-ag-2548962 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.